Build the Wall: How Pharma Companies Layer NCE and Orphan Drug Exclusivity to Lock Out Generics
Pharmaceutical executives routinely talk about patent cliffs as if they were acts of nature. They are not. The shape of […]
Pharmaceutical executives routinely talk about patent cliffs as if they were acts of nature. They are not. The shape of […]
A strategic analysis for pharmaceutical companies, generic manufacturers, investors, and policy professionals The Indian Clock In most patent systems, the
Every major pharmaceutical patent war starts with a single form filed with the FDA. It is not a lawsuit. No
How litigation patterns, settlement timelines, and competitive pressure in biologics are rewriting the industry’s talent map — and what that
Biosimilar Patent Wars Reveal Exactly Where Biopharma Talent Is Heading Next Read Post »
The Clock You Are Ignoring Every branded drug in the specialty channel has an expiration date that has nothing to
The Patent Clock Is a Sales Calendar Every drug patent that expires is a starting gun, not a finish line.
There’s a certain genre of drug question that never goes out of style: “Can this thing I’m already taking also
Can This Drug…Do That? The internet keeps asking. The pharmacology keeps sighing. Read Post »
Courts can triple damages for willful infringement. A flawed freedom-to-operate search is not a defense — it is evidence you
Unit price is the number everyone fights over. It’s also the number that matters least. Pharmaceutical procurement has a dirty
The Real Price of a Drug: A Total Cost of Ownership Model for Pharma Procurement Teams Read Post »
Get fresh news and insights, drug patent expirations & more…